Targeted cancer drugs finally living up to the hype

Targeted cancer drugs finally living up to the hype
Big pharmaceutical companies are backing so-called antibody-drug conjugates. (Image: Bloomberg)
Bloomberg
By Lisa JarvisCancer drugs that work like heat-seeking missiles to deliver chemicals directly to tumours are having a bit of a moment. Pharmaceutical companies, in need of assets to counter flagging sales, are making these so-called antibody-drug conjugates the technology of choice in oncology dealmaking, as illustrated by the recent US$10.1 billion (NZ$16.5b) acquisition of ImmunoGen by AbbVie.If that trend sounds vaguely familiar, you have probably been following the pharma industry for too long. The field has gone through waves of hype and i...

More Bloomberg

China floods the world with AI models after DeepSeek’s success
Technology

China floods the world with AI models after DeepSeek’s success

Long-dormant Chinese tech sector now fired up, and Western rivals may pay the price.

Bloomberg 29 Mar 2025
Thailand plans to cut tourists’ visa-free stays to 30 days
Travel

Thailand plans to cut tourists’ visa-free stays to 30 days

Govt cracking down on travellers exploiting the waiver to engage in illegal businesses.

Bloomberg 23 Mar 2025
Fears for 1,000 wind projects as German election nears
Energy

Fears for 1,000 wind projects as German election nears

Expansion of energy source is at risk of a drastic slowdown, industry group says.

Bloomberg 01 Feb 2025
UK burying Thatcher’s privatisation legacy
Policy Opinion

UK burying Thatcher’s privatisation legacy

Experience with privatised public services has soured.

Bloomberg 04 Jan 2025